Molecular Case Studies · 2018 · 23 citations · 44 references
MedicineMolecular GeneticsOncologyGenomicsMetastasisMolecular OncologyCancer GenomicsCancer ProgressionMalignant NeoplasmsMolecular Tumor ProfilingNext-generation Sequencing In OncologyOncogene MutationsCancer Mutation SignaturesMyb-nfib FusionNext-generation Sequencing AnalysisTranscriptome ProfilingTranscriptome SequencingTumor Mutational BurdenTumor Mutational Burden AssessmentWhole-genome Sequencing Analysis
Metastatic adenoid cystic carcinomas (ACCs) can cause significant morbidity and mortality. Because of their slow growth and relative rarity, there is limited evidence for systemic therapy regimens. Recently, molecular profiling studies have begun to reveal the genetic landscape of these poorly understood cancers, and new treatment possibilities are beginning to emerge. The objective is to use whole-genome and transcriptome sequencing and analysis to better understand the genetic alterations underlying the pathology of metastatic and rare ACCs and determine potentially actionable therapeutic targets. We report five cases of metastatic ACC, not originating in the salivary glands, in patients enrolled in the Personalized Oncogenomics (POG) Program at the BC Cancer Agency. Genomic workup included whole-genome and transcriptome sequencing, detailed analysis of tumor alterations, and integration with existing knowledge of drug–target combinations to identify potential therapeutic targets. Analysis reveals low mutational burden in these five ACC cases, and mutation signatures that are commonly observed in multiple cancer types. Notably, the only recurrent structural aberration identified was the well-described MYB-NFIB fusion that was present in four of five cases, and one case exhibited a closely related MYBL1-NFIB fusion. Recurrent mutations were also identified in BAP1 and BCOR, with additional mutations in individual samples affecting NOTCH1 and the epigenetic regulators ARID2, SMARCA2, and SMARCB1. Copy changes were rare, and they included amplification of MYC and homozygous loss of CDKN2A in individual samples. Genomic analysis revealed therapeutic targets in all five cases and served to inform a therapeutic choice in three of the cases to date.
44
Ethan Cerami, Jianjiong Gao, Uğur Doğrusöz et al. · Cancer Discovery · 2012 · 18.4K citations · Full text
Medicine, Bioinformatics, Oncology +15
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao, Bülent Arman Aksoy, Uğur Doğrusöz et al. · Science Signaling · 2013 · 15.9K citations · Full text
Medicine, Bioinformatics, Oncology +17
Circos: An information aesthetic for comparative genomics
Martin Krzywinski, Jacqueline E. Schein, İnanç Birol et al. · Genome Research · 2009 · 11.9K citations · Full text
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein, Gordon B. Mills, Kenna Shaw et al. · Nature Genetics · 2013 · 9.5K citations · Full text
ABySS: A parallel assembler for short read sequence data
Jared T. Simpson, Kim Wong, Shaun D. Jackman et al. · Genome Research · 2009 · 3.8K citations · Full text
Life Sciences, Biology, Genetics +17